
    
      PROTOCOL OUTLINE: This is a randomized, double-blind, placebo controlled study. Patients are
      randomly assigned to receive placebo or conjugated estrogens and, if no prior hysterectomy,
      medroxyprogesterone. Patients also receive calcium supplementation therapy daily for 3 years.

      Participants in the placebo group may be removed from study if bone loss exceeds 5% per year.

      A study duration of 3 years is anticipated.
    
  